Skip to content

Ayurvedic intervention (Chyawanprash) in the prevention of COVID-19 pandemic among Health Care Personnel

Evaluation of the efficacy of an Ayurvedic intervention (Chyawanprash) in the prevention of COVID-19 pandemic among Health Care Personnel â?? An open label single arm prospective study

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025425
Enrollment
50
Registered
2020-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Chayapanprash (an Ayurvedic herbal preparation): Dose: 12 g twice daily. Dosage form : Avaleha. Route of Administration : Oral. Time of Administration : Twice in a day- On empty stomac

Sponsors

Central Council For Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All healthcare professionals of 20 to 60 years willing to participate, who were negative for SARS- Cov-2 at screening, (tested by RT-PCR), at A & U, Tibbia hospital dealing with COVID-19, with or without co-morbid condition with exposure/chance of exposure to COVID 19 positive cases. 2. Those who are willing to provide signed informed consent. 3. High Risk Group- It includes doctors, nursing staff and other paramedical staff like attendant who are directly looking after and examining COVID patients. 4. Low risk- other faculty members who are present in the institute but not visiting corona ward.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating females. 2. Known case of Carcinoma lungs, CRF and CHF. 3. Participants with any immunosuppressive medication or in an immune compromised state or hematological disease. 4. Laboratory confirmed COVID-19 with or without symptoms. 5. DM uncontrolled with medications. 6. Any other criteria, as per the investigator would jeopardize the study.

Design outcomes

Primary

MeasureTime frame
1. Percentage of participants with SARS- Cov-2 positivity as estimated by RT-PCR of nasopharyngeal swab.Timepoint: Assessment on baseline and at the end of study that is 30th day

Secondary

MeasureTime frame
1. Safety profile of the intervention as estimated by LFT, KFT and other hematological & biochemical investigations. Timepoint: Time frame : 30 days

Countries

India

Contacts

Public ContactDr Shivshankar Rajput

CCRAS, J.L.N.B.C.A.H. Anusandhan Bhawan,no. 61-65, Institutional area, opposite D Block, Janakpuri

drbabitayadav@gmail.com9910171143

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026